Patents Assigned to INCYCLIX BIO, LLC
  • ADVANTAGEOUS HUMAN DOSAGE REGIMENS FOR ADMINISTRATION OF INX-315
    Publication number: 20260041640
    Abstract: Dosages and regimens based on the discovery of unexpectedly high and sustained exposure of INX-315 in humans in need thereof which results in increased efficacy per dose and minimizes adverse events during treatment, including by minimizing the ratio of Cmax to Cmin, resulting in a decrease in an initial drug spike after administration.
    Type: Application
    Filed: October 17, 2025
    Publication date: February 12, 2026
    Applicant: INCYCLIX BIO, LLC
    Inventors: Jay Copeland Strum, Alexander Smith, Patrick Joseph Roberts, Erica Schlesinger, Randy J. Wald, Cindy Chung, Wesley K. Tatum
  • CYCLIN-DEPENDENT KINASE 2 INHIBITORS FOR MEDICAL TREATMENT
    Publication number: 20250199015
    Abstract: Use of a pyrimidine-based selective cyclin-dependent kinase 2 (CDK2) of structure: or a pharmaceutically acceptable salt thereof or morphic form described herein for the treatment of disorders characterized by aberrant cellular division having amplified cyclin E activation and/or expression or aberrant cellular division disorders, CDK4/6 resistance, and/or endocrine therapy resistance, including but not limited to the treatment of tumors and cancers.
    Type: Application
    Filed: December 20, 2024
    Publication date: June 19, 2025
    Applicant: INCYCLIX BIO, LLC
    Inventors: Jay Copeland Strum, John E. Bisi, Alec Gibson Trub